Using 2-year OS as outcome, the NPV of I-PET and EoT-PET was high (range 81.8–94.1%), and higher for both I-PET and EoT-PET in the MYC- DLBCL patients compared to the MYC + DLBCL patients (Table 4). The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.